Wild-type virus

J ,3J ,4J ,5J )-2,5-bis(benzyloxy)-3,4-dihydroxy-Nd -bis (lS)-2-methyl-l-[(methylamino)carbonyl]propyl hexanediamide is a C2-symmetric HIV-1 protease inhibitor [29]. Derivatization in the para positions of the benzyl-oxy groups via microwave-assisted Stille reaction on the corresponding di-brominated inhibitor smoothly yielded the desired heteroarylated derivatives (Scheme 10). Interestingly, the 1,3-thiazole derivative showed a higher antiviral activity on the wild type virus than the lead compound. The activity remained at the same level in the presence of seriun. Unfortimately, a low activity was observed on mutants. 

Bukovsky AA, Song JP, Naldini L (1999) Interaction of human immunodeficiency virus-derived vectors with wild-type virus in transduced cells. J Virol 73 7087-7092... 

Trono D, Feinberg MB, Baltimore D (1989) HlV-1 Gag mutants can dominantly interfere with the replication of the wild-type virus. Cell 59 113-120 Tung FY, Bowen SW (1998) Targeted inhibition of hepatitis B virus gene expression a gene therapy approach. Front Biosci 3 all-al5... 

Fig. 1 Three phases in viral evolution during suboptimal therapy. The black hne represents wild type virus, whereas the red line represents mutant virus (Res stands for the level of resistance and RC for replication capacity).

Secondary transmission to household contacts is always a concern with administration of a live vaccine. There are a few cases of possible secondary transmission of varicella following vaccination. Of the cases that varicella typing was done, 62% were wild-type virus, indicating exposure to an unvaccinated person. There are less than 10 confirmed cases of secondary transmission of the Oka vaccine strain following vaccination. A mild rash occurring in less than 5% of persons has been reported following vaccination. The varicella virus may be shed from the rash. Rashes due to the Oka vaccine strain typically occur more than 20 days following vaccination.12... 

From pilot studies carried out in the clinic with the NNRTIs TIBO R82913 [75] and pyridinone L-697,661 [76], it appears that the compounds are well tolerated and do not cause toxic side effects. Most of the HIV-1 isolates obtained from the patients treated with TIBO R82913 appeared to be as sensitive to the compound as wild-type virus only two HIV-1 variants were isolated, showing a sensitivity that was reduced 20-fold or more than 100-fold, the latter being caused by a mutation (Tyr —> Leu) at position 188 of the RT [77]. In fact, the latter mutation was lost upon passaging the virus in vitro in cord blood lymphocytes. Following treatment of the patients with pyridinone L-697,661, drug-resistant HIV-1 variants appeared that contained mutations at the RT positions 103 (Lys —> Asn) and 181 (Tyr —> Cys) [76]. 

In vitro challenge studies evaluation of recombination or complementation, potential for rescue for subsequent infection with wild-type virus. 

The most scientific approach is to replicate, in an appropriate animal, the type of dosing that would be expected to be used in humans, employing the dose for dose animal to human principle. A single, suitable animal species should suffice. If viral vectors are used, the animal species should be sensitive to infection by the wild-type virus. Studies should not automatically be done in primates but, initially, the commonly used laboratory species should be utilized. Only if those are demonstrated to be unsuitable should the next step be to consider the use of a primate. 

Folate for targeting diverse tumors (transduction inhibited in folate receptor-negative control cells, transduction like wild-type virus in folate receptor-positive cells) [13]... 

Clark, K. R., Liu, X., McGrath, J. P. and Johnson, P. R. (1999). Highly purified recombinant adeno-associated virus vectors are biologically active and free of detectable helper and wild-type viruses [In Process Citation]. Hum. Gene Ther. 10, 1031 1039. 

Remove medium by vacuum aspiration, and add 0.4 mL of Ex-Cell 400 medium. Add 0.1 mL of PI virus stock (approx 2 1 x 107 pfu/mL) or appropriate control wild-type virus (approx multiplicity of infection [MOI] of 1 to 10). 

Faecal excretion of vaccine virus will occur and may last for up to 6 weeks post-treatment. Such released virus will spread to close contacts and infect/(re-)immunize them. Vaccine-associated poliomyelitis may occur through reversion of the attenuated strains to the virulent wild-type, particularly with types II and III and is estimated to occur once per 4 million doses. As the wild-type virus can be isolated in faeces, infection may occur in unimmunized contacts as well as vaccine recipients. Since the introduction of OPV, notifications of paralytic poliomyelitis in the UK have dropped spectacularly. However, from 1985 to 1995,19 of the 28 notified cases of paralytic poliomyelitis were associated with revertant vaccine strains (14 recipients, 5 contacts). As the risk of natural infections with poliomyelitis within developed countries has now diminished markedly, the greater risk resides with the live vaccine strains. Proposals are therefore now being considered that in the developed world OPV should be replaced with IPV. 

---